Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Website: www.atossatherapeutics.com

Address:

448 NW Market Street, Suite 500, Seattle, United States

Babyballoon Jul. 4 at 3:10 PM

$ATOS didn’t you promise to leave this board and NEVER return if the price dipped under $2? You lost a bet with @Warrens__Buffet_ a month ago and, as predicted, couldn’t keep your promise 😂. Because scammers aren’t known for their integrity.

2 · Reply

Michaeljin_101 Jul. 4 at 1:23 PM

$ATOS Celebrating the 250th anniversary of our nation’s founding! Enjoy this scene I created with AI—a book cover for Sir Walter Scott’s The Pirate—purely for literary enjoyment!

0 · Reply

Kittyc803 Jul. 4 at 11:51 AM

$ATOS Happy 😃 Inependence day people . 🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸

1 · Reply

The_Real_Heisenberg Jul. 4 at 2:20 AM

$ATOS https://youtu.be/4oxZ9w_WuYY?si=aKBjWmt0ePzWxJkx

0 · Reply

RichardDangler Jul. 4 at 12:47 AM

$ATOS happy 4th everyone - hoping the second half brings some excitement. Evangeline and iSPY data coming this half. Let’s see if the wait will be worth it !

0 · Reply

JDAAT Jul. 2 at 11:59 PM

$ATOS Tomorrow market is closed

0 · Reply

The_Real_Heisenberg Jul. 2 at 10:57 PM

$ATOS every single person on this board views you as a moron. Every post you make demonstrates it more and more. You insult others when they didnt provoke you. Your statements are loaded with emotion. Go back to kindergarten. Investing is for big boys.

1 · Reply

Babyballoon Jul. 2 at 8:30 PM

$ATOS your stupidity continues to show. Take a moment, pretend to not be stupid, and tell me what the ATOS price action was during the week immediately following the two bullish comments you picked from my profile. And then once you realize how much of a fucking clown you are, come back here with your next attempt to save face. 😂

1 · Reply

Babyballoon Jul. 2 at 8:26 PM

$ATOS every stock? Another moron sharing his thoughts. Why don’t go ahead and tell the world what I’ve been saying about SLS? Or stay retarded. Your choice 😂

1 · Reply

Babyballoon Jul. 2 at 8:20 PM

$ATOS one of the funniest things you’ll ever see on the internet is someone repeatedly replying to you while telling you that “no one cares” about my posts. You’re doing an excellent job showing everyone why I was correct to label you as a moron 😂😂

0 · Reply

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

2026-06-11T12:07:04.000Z - 23 days ago

Atossa Therapeutics announces registered direct offering of up to $16.5M

2026-06-11T12:06:50.000Z - 23 days ago

Atossa Therapeutics announces $16.5M registered direct offering

Jun 11, 2026, 8:00 AM EDT - 23 days ago

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

May 27, 2026, 8:30 AM EDT - 5 weeks ago

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

May 20, 2026, 4:45 PM EDT - 6 weeks ago

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

May 19, 2026, 4:00 PM EDT - 6 weeks ago

Atossa Therapeutics Transcript: Status update

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

2026-05-08T16:29:20.000Z - 2 months ago

Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year

May 8, 2026, 8:45 AM EDT - 2 months ago

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 8, 2026, 7:00 AM EDT - 2 months ago

Atossa Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 2 months ago

Atossa Therapeutics Earnings release: Q1 2026

2026-05-07T05:43:04.000Z - 2 months ago

Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial

May 6, 2026, 8:30 AM EDT - 2 months ago

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

2026-05-04T13:09:59.000Z - 2 months ago

Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS

May 4, 2026, 8:30 AM EDT - 2 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Atossa Therapeutics Proxy statement: Proxy filing

2026-03-26T11:21:53.000Z - 3 months ago

Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright

2026-03-25T21:40:26.000Z - 3 months ago

Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)

Mar 25, 2026, 5:30 PM EDT - 3 months ago

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Mar 25, 2026, 7:00 AM EDT - 3 months ago

Atossa Therapeutics Earnings release: Q4 2025

Mar 25, 2026, 7:00 AM EDT - 3 months ago

Atossa Therapeutics Annual report: Q4 2025

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Atossa Therapeutics Proxy statement: Proxy filing

2026-03-19T12:07:12.000Z - 3 months ago

Atossa Therapeutics announces addition of two biopharma executives to team

Mar 19, 2026, 8:00 AM EDT - 3 months ago

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Mar 12, 2026, 8:00 AM EDT - 4 months ago

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

2026-02-12T14:20:21.000Z - 5 months ago

Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum

Feb 11, 2026, 8:30 AM EST - 5 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Feb 11, 2026, 6:00 AM EST - 5 months ago

Atossa Therapeutics Slides: Corporate presentation

Feb 5, 2026, 8:30 AM EST - 5 months ago

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Jan 21, 2026, 9:05 AM EST - 5 months ago

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

2026-01-16T21:45:23.000Z - 6 months ago

Atossa Therapeutics: FDA grants orphan designation to (Z)-endoxifen

Jan 16, 2026, 4:40 PM EST - 6 months ago

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

2026-01-16T02:40:18.000Z - 6 months ago

FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen

2026-01-06T13:21:47.000Z - 6 months ago

Atossa Therapeutics receives “Study May Proceed” letter for breast cancer study

Jan 6, 2026, 8:15 AM EST - 6 months ago

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Dec 22, 2025, 7:00 AM EST - 6 months ago

Atossa Therapeutics Proxy statement: Proxy Filing

Dec 17, 2025, 8:15 AM EST - 7 months ago

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

2025-12-15T13:10:50.000Z - 7 months ago

Atossa Therapeutics presents four trial updates on Z-endoxifen

Dec 15, 2025, 8:00 AM EST - 7 months ago

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Dec 12, 2025, 7:00 AM EST - 7 months ago

Atossa Therapeutics Proxy statement: Proxy Filing

2025-12-11T13:05:52.000Z - 7 months ago

Atossa Therapeutics receives FDA RPD designation to (Z)-Endoxifen

Dec 11, 2025, 8:00 AM EST - 7 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Dec 9, 2025, 8:00 AM EST - 7 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Dec 4, 2025, 8:00 AM EST - 7 months ago

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Dec 2, 2025, 8:00 AM EST - 7 months ago

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Nov 17, 2025, 9:07 AM EST - 8 months ago

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Nov 12, 2025, 8:30 AM EST - 8 months ago

Atossa Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

Atossa Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:15 AM EST - 8 months ago

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 8 months ago

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Oct 21, 2025, 8:00 AM EDT - 9 months ago

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 9 months ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 9 months ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 9 months ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 9 months ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 10 months ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 3:00 PM EDT - 10 months ago

Atossa Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 8:30 AM EDT - 10 months ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 11 months ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Earnings release: Q2 2025

Jul 29, 2025, 7:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 5, 2025, 8:10 AM EDT - 1 year ago

Atossa Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Transcript: Status Update

May 20, 2025, 9:00 AM EDT - 1 year ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Quarterly report: Q1 2025

Apr 30, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Proxy statement: Proxy Filing

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings Call Transcript: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Annual report: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Slides: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 1 year ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Feb 5, 2025, 8:00 AM EST - 1 year ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Jan 30, 2025, 8:17 AM EST - 1 year ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Babyballoon Jul. 4 at 3:10 PM

2 · Reply

Michaeljin_101 Jul. 4 at 1:23 PM

$ATOS Celebrating the 250th anniversary of our nation’s founding! Enjoy this scene I created with AI—a book cover for Sir Walter Scott’s The Pirate—purely for literary enjoyment!

0 · Reply

Kittyc803 Jul. 4 at 11:51 AM

$ATOS Happy 😃 Inependence day people . 🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸🇺🇸

1 · Reply

The_Real_Heisenberg Jul. 4 at 2:20 AM

$ATOS https://youtu.be/4oxZ9w_WuYY?si=aKBjWmt0ePzWxJkx

0 · Reply

RichardDangler Jul. 4 at 12:47 AM

$ATOS happy 4th everyone - hoping the second half brings some excitement. Evangeline and iSPY data coming this half. Let’s see if the wait will be worth it !

0 · Reply

JDAAT Jul. 2 at 11:59 PM

$ATOS Tomorrow market is closed

0 · Reply

The_Real_Heisenberg Jul. 2 at 10:57 PM

1 · Reply

Babyballoon Jul. 2 at 8:30 PM

1 · Reply

Babyballoon Jul. 2 at 8:26 PM

$ATOS every stock? Another moron sharing his thoughts. Why don’t go ahead and tell the world what I’ve been saying about SLS? Or stay retarded. Your choice 😂

1 · Reply

Babyballoon Jul. 2 at 8:20 PM

0 · Reply

Bunster Jul. 2 at 7:16 PM

$ATOS this is baby balloon s post that says it all girls. Yes sick of Dr quays lies .Baby balloon u and in and out have common ground. u both have posted u r sick of dr quays lies.

1 · Reply

Babyballoon Jul. 2 at 6:31 PM

$ATOS what’s there to think about? Your daughter is right. And since the CEO is still the same guy fleecing investors, your decision should already be made.

0 · Reply

Babyballoon Jul. 2 at 6:29 PM

$ATOS dumbass, I sold my holdings in January pre-RS. Scammer is so desperate to regain credibility that he has to go back to before TWO RS votes in order to find me saying something positive about this trash stock

1 · Reply

Babyballoon Jul. 2 at 6:26 PM

$ATOS wow, you’re retarded. Yes, I supported $ATOS almost a year ago when the fundamentals were better. Fundamentals have been shit for ~6+ months. Anyone who listened to me when I switched to bearish would’ve avoided a 75% loss, moron. This stock is trash and I’ll keep calling out scammers like you.

1 · Reply

JinxAndJazzy Jul. 2 at 6:11 PM

$ATOS Talking with my 15 yo daughter, explaining the backstory here and why it’s an important one for the market. Her response at the end was “Sounds to me like you just need a new CEO.” 😂 Thinking about getting back in this one. Still a little shy on it.

0 · Reply

dcajic2 Jul. 2 at 4:46 PM

$ATOS Bullish nonsense. I am shorting every single pop. Reality land. Where is the news that is driving the stock higher? Volume is weak.

0 · Reply

RichardDangler Jul. 2 at 3:40 PM

$ATOS the guy is a bitter bagholder like I said… don’t let him fool you guys. He’s not “looking out for others.” This guy is pathetic 😂😂

1 · Reply

dcajic2 Jul. 2 at 2:28 PM

$ATOS shorting more. Makes literal no sense why it’s higher.

0 · Reply

RichardDangler Jul. 2 at 2:04 PM

$ATOS just remember folks, this guy was a huge bull attacking bears not too long ago 😂

2 · Reply

dcajic2 Jul. 2 at 2:03 PM

$ATOS makes zero sense why it’s higher. They need big money just to survive phase 3. They are only in phase 2 and no data to be released until end of year. They haven’t even begun the bigger phase 2 study. This management team only cares about themselves and zero about shareholders. If they had cared about shareholders they would have got a partner along time ago or they would have sold the entire company. Now it’s just a waiting game for dilution and then it will be off the market.

0 · Reply

RichardDangler Jul. 2 at 1:58 PM

$ATOS those $1.70 buys doing well right now. Where’s @Bunster ?

0 · Reply

DCalcote Jul. 2 at 1:57 PM

$ATOS

0 · Reply

Market Cap	18.26M
Revenue (ttm)	0.00
Net Income (ttm)	-34.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	116,500
Avg Vol	156,360
Day's Range	N/A - N/A
Shares Out	8.61M
Stochastic %K	86%
Beta	1.25
Analysts	Strong Sell
Price Target	$22.00